Press Release – LOS ANGELES, CALIFORNIA – 05/23/2018 (PRESS RELEASE JET) – Leonhardt’s Lauchhpads an innovation and startup accelerator www.leonhardtventures.com focused on organ regeneration and recovery technologies based in Los Angeles and Salt Lake City and DeviceLab, Inc. an Orange County, California medical product design and development company, today announced that they have launched a working partnership with DeviceLab’s engineers engaged to build prototypes for many of the 30 startups in the Leonhardt’s Launchpads accelerator(s).
“Leonhardt inventions have treated with success over 400,000 patients to date. The team assembled by Leonhardt’s Launchpads 140 strong has a proven track record of bringing concepts to market leadership in the area of organ regeneration and recovery technologies. It is a great honor to be selected by this organization as their go to prototype building shop for their 30+ startups.” said DeviceLab founder and CEO Doc Vu
“DeviceLab has proven themselves in rapid prototyping which we view as a critical element to the success of the startups in our innovation accelerator. Their team has experience with over 100 product developments and their reference list is impressive. We love that they are located just a 45 miles south of our headquarters where we can meet with their team in person to drive projects forward with good communication.” states Alex Richardson Vice President of Engineering and Product Development at Leonhardt’s Launchpads
Leonhardt’s Launchpads innovation and startup accelerator(s) have these active projects in these sectors.
- Heart & Cardiovascular (9) – heart, biological pacemaker, heart valve, diabetic ulcers, blood pressure and aorta regeneration.
- Brain (1) – stroke and traumatic brain injury recovery, Parkinson’s, Alzheimers, Bran-N-Hance brain cognitive function enhancement – www.cerebracell.com
- Cosmetic & Personal Care (6) – breast tissue generation, dental gums & teeth, accelerated tooth movement & stabilization, skin, hair, erectile dysfunction.
- Major Organ Regeneration (11) – eye, pancreas, lung, liver, kidney, ear hearing, bladder, polyps/mucosa, inflammation, knees, joints, bones, tendons, whole body regeneration.
- Cancer (1) – bioelectric and biologics cancer treatment including inflammation control – www.cancercellinc.com
The first projects DeviceLabs is working on for Leonhardt’s Launchpads include:
- OrthodontiCell Tooth Movement AcceleratorTM www.orthodonticell.com and teeth position stabilizer.
- Valvublator heart valve decalcification and regeneration device www.valvublator.com so patients can keep their own heart valve instead of getting an artificial implant.
About Leonhardt’s Launchpads: An innovation and startup accelerator with labs and offices in California and Utah focused on organ regeneration and recovery technologies. 30 startups in the current 2018 portfolio class. Business model is to accelerate each organ specific innovation through first-in-man studies and then seek a strategic partner/buyer.
About Leonhardt Ventures: Since 1982 bringing forward medtech innovations. In the 1980’s the team developed a leadership position in cardiovascular balloon catheters, in the 1990’s in stent grafts and percutaneous heart valves, in the 2000’s in stem cell based therapies and since 2010 the focus has been on the combination of bioelectric stimulation + a refillable micro infusion pump + a fifteen component composition for organ regeneration. Over 21 issued patents and dozens of more patent claims pending. Over 400,000 patients treated with inventions to date.
DeviceLab: Established in 1998, DeviceLab is a full-service, consumer, medical device engineering and design company based in Orange County, Southern California – https://www.devicelab.com
Caution: All innovations mentioned are in the early stages of development and are not yet proven safe of effective. Patents pending may not be issued. Patents licensed may not be maintained. Startups have substantially less resources than comparable competitors and may not be able to bring these innovations through first-in-man studies.